GRIN2A-Related Epilepsy

GRIN2A-Related Epilepsy

Overview

GRIN2A-related epilepsy (also known as GRIN2A-related developmental and epileptic encephalopathy) is a genetic disorder caused by pathogenic variants in the GRIN2A gene. This condition is part of the epilepsy-aphasia spectrum (EAS), which includes Landau-Kleffner syndrome (LKS) and other childhood-onset epilepsies with speech and language disturbances. GRIN2A variants are among the most common genetic causes of focal epilepsy with speech and language regression[@grin2a_overview_2020].

The GRIN2A gene encodes the GluN2A subunit (formerly NR2A) of the NMDA receptor, a critical ion channel for synaptic plasticity, learning, and memory. Pathogenic variants typically cause loss-of-function, leading to dysregulated NMDA receptor signaling and disrupted cortical development.

Genetics and Molecular Basis

GRIN2A Gene

[GRIN2A](/genes/grin2a) (Glutamate Ionotropic Receptor NMDA Type Subunit 2A) is located on chromosome 16p13.2 and encodes the GluN2A NMDA receptor subunit. The gene contains 14 exons and spans approximately 250 kb. Over 200 pathogenic variants have been identified:

• Missense variants (~60%): amino acid substitutions affecting receptor function
• Nonsense/frameshift variants (~25%): premature stop codons
• Splice site variants (~15%): aberrant mRNA processing

Pathogenic variants follow an autosomal dominant inheritance pattern with high penetrance. Most variants are de novo, though family transmission can occur.

Pathophysiology

GRIN2A variants disrupt NMDA receptor function:

...

GRIN2A-Related Epilepsy

Overview

GRIN2A-related epilepsy (also known as GRIN2A-related developmental and epileptic encephalopathy) is a genetic disorder caused by pathogenic variants in the GRIN2A gene. This condition is part of the epilepsy-aphasia spectrum (EAS), which includes Landau-Kleffner syndrome (LKS) and other childhood-onset epilepsies with speech and language disturbances. GRIN2A variants are among the most common genetic causes of focal epilepsy with speech and language regression[@grin2a_overview_2020].

The GRIN2A gene encodes the GluN2A subunit (formerly NR2A) of the NMDA receptor, a critical ion channel for synaptic plasticity, learning, and memory. Pathogenic variants typically cause loss-of-function, leading to dysregulated NMDA receptor signaling and disrupted cortical development.

Genetics and Molecular Basis

GRIN2A Gene

[GRIN2A](/genes/grin2a) (Glutamate Ionotropic Receptor NMDA Type Subunit 2A) is located on chromosome 16p13.2 and encodes the GluN2A NMDA receptor subunit. The gene contains 14 exons and spans approximately 250 kb. Over 200 pathogenic variants have been identified:

• Missense variants (~60%): amino acid substitutions affecting receptor function
• Nonsense/frameshift variants (~25%): premature stop codons
• Splice site variants (~15%): aberrant mRNA processing

Pathogenic variants follow an autosomal dominant inheritance pattern with high penetrance. Most variants are de novo, though family transmission can occur.

Pathophysiology

GRIN2A variants disrupt NMDA receptor function:

Receptor assembly — GluN2A partners with GluN1 to form functional NMDA receptors

Synaptic plasticity — NMDA receptors mediate calcium influx critical for LTP and LTD

Cortical development — Dysregulated signaling disrupts neuronal migration and synapse formation

Speech and language circuits — Specific vulnerability of perisylvian cortex explains language regression

The epilepsy-aphasia spectrum results from focal cortical dysplasia and abnormal synchronization of speech-related brain networks.

Epidemiology

| Metric | Value |
|--------|-------|
| Prevalence | ~1:100,000–200,000 |
| Incidence | ~1:50,000–100,000 live births |
| Sex ratio | Slight male predominance (1.3:1) |
| Family recurrence | <10% (mostly de novo) |
| EAS proportion | ~20% of Landau-Kleffner cases |

GRIN2A variants account for approximately 10-20% of epilepsy-aphasia spectrum cases and 5-10% of focal epilepsy with Rolandic spikes.

Clinical Presentation

Seizure Types

Epilepsy typically presents between 2-10 years of age. Key seizure types include:

• Focal seizures (most common): typically involving perisylvian regions
• Atypical absence seizures: brief staring episodes
• Electrical status epilepticus during sleep (ESES): continuous spike-wave during sleep
• Generalized tonic-clonic seizures: less common

Landau-Kleffner Syndrome

A subset of patients develop classic LKS:

• Speech regression: progressive loss of verbal communication
• Auditory agnosia: inability to recognize sounds or speech
• Seizures: typically focal, may be infrequent
• EEG abnormalities: spike-wave in temporal regions, especially during sleep

Developmental Profile

• Early development: Typically normal in the first 1-2 years
• Language regression: Often the presenting symptom between ages 3-7
• Intellectual disability: Variable — mild to severe
• Speech: May be severely affected, ranging from mild dysarthria to complete loss

Comorbidities

• Speech and language disorders (in ~90%)
• Autism spectrum features (in ~30%)
• Attention-deficit/hyperactivity disorder (in ~25%)
• Behavioral problems (in ~20%)
• Movement disorders (rare)

Diagnosis

Genetic Testing

GRIN2A-related epilepsy is diagnosed through molecular genetic testing:

• Epilepsy gene panel: First-tier test including GRIN2A
• Whole exome sequencing: Increasingly used as first-tier test
• Genome sequencing: For detection of structural variants

Electroencephalography

EEG findings are characteristic:

• Interictal: Focal spike-wave in centrotemporal (Rolandic) regions
• ESES: Continuous spike-wave during slow-wave sleep (in ~30%)
• Temporal focus: Left-sided predominance in speech-related cases

Imaging

MRI is typically normal but may show:

• Focal cortical dysplasia in some cases
• Temporal lobe abnormalities (less common)

Treatment

Anti-Seizure Medications

Standard ASMs may provide partial control:

| Medication | Efficacy | Notes |
|------------|----------|-------|
| Levetiracetam | Partial | First-line for focal seizures |
| Valproic acid | Partial | Broad-spectrum |
| Clobazam | Partial | May worsen sleep EEG |
| Sulthiame | Variable | Particularly for ESES |
| Steroids/ACTH | Variable | For ESES |

Immunotherapy

• Corticosteroids: Often effective for ESES and speech regression
• IVIG: Reported benefit in some cases
• Ketogenic diet: May help refractory cases

Non-Pharmacological Treatments

• Vagus nerve stimulation (VNS): May reduce seizures
• Dietary therapies: Ketogenic diet for refractory cases
• Speech therapy: Critical for language rehabilitation

Gene Therapy Considerations

Therapeutic Approaches

GRIN2A is an attractive target for gene therapy due to:

| Factor | Assessment |
|--------|------------|
| Gene size | ~4.3 kb coding sequence — near AAV limit |
| Mechanism | Loss-of-function — gene replacement approach |
| Timing | Early intervention before speech regression |
| Brain regions | Perisylvian cortex — accessible via ICM |

Challenges

Gene size — Full-length GRIN2A (~4.3 kb) approaches AAV packaging limit

Expression timing — NMDA receptor subunit composition changes with age

Cell-type specificity — Need appropriate promoter for neuronal expression

Timing window — Critical period for speech development

Programs to Track

| Entity | Status | Approach |
|--------|--------|----------|
| Academic groups | Research | AAV-GRIN2A delivery |
| Various ASO programs | Discovery | Splice-modulating ASOs |

The development of miniature/optimized GRIN2A constructs or dual-AAV approaches may enable clinical translation.

Research Landscape

Natural History Studies

Several studies are characterizing GRIN2A-related epilepsy:

• Epilepsy Genetics Consortium — genotype-phenotype correlations
• Rare Disease Consortium — developmental outcomes

Key Publications

[GRIN2A mutations in epilepsy-aphasia spectrum (Nature Genetics, 2013)](https://pubmed.ncbi.nlm.nih.gov/24265613/)

[Landau-Kleffner syndrome and GRIN2A (Brain, 2015)](https://pubmed.ncbi.nlm.nih.gov/25808374/)

[GRIN2A-related developmental epileptic encephalopathy (Brain, 2020)](https://pubmed.ncbi.nlm.nih.gov/32040920/)

[ESES and GRIN2A: phenotype correlation (Epilepsia, 2019)](https://pubmed.ncbi.nlm.nih.gov/30663782/)

Research Groups

• University of Washington (UW) — GRIN2A genotype-phenotype studies
• Boston Children's Hospital — Epilepsy genetics and therapeutics
• University of Melbourne — LKS natural history

Patient Support

Organizations

• [CURE Epilepsy](https://cureepilepsy.org/) — General epilepsy research funding
• [LKS Foundation](https://www.lksfoundation.org/) — Landau-Kleffner syndrome support (US-based)

Resources

• ClinicalTrials.gov — Search for GRIN2A-related studies
• GeneReviews — GRIN2A-related epilepsy entry
• Epilepsy Foundation — Resources for genetic epilepsies

References

<!-- Auto-populated by sync system -->